Market Cap 97.82M
Revenue (ttm) 7.95M
Net Income (ttm) -21.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -267.04%
Debt to Equity Ratio 0.00
Volume 130,678
Avg Vol 141,568
Day's Range N/A - N/A
Shares Out 23.46M
Stochastic %K 84%
Beta 0.51
Analysts Strong Sell
Price Target $15.64

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
RealAvidTrader
RealAvidTrader Apr. 14 at 8:27 PM
$GANX $COYA Nice Health Consolidation Day - Gearing Up For Bigger Moves Later in The Year. Shareholders Should Be Very Excited, Optimistic For The Future. I Certainly Am!
0 · Reply
irf944
irf944 Apr. 14 at 2:18 PM
$COYA Pont & Figure chart update. I use P&F charts since they take the noise out of the daily volatility and trading prices. Coya had to omove from $3.75 to $4.50 to denote a change from Sellers/Supply (denoted by "O"), to Buyers/Demand (denoted by "X"). The stock is currently in the hands of buyers/demand, the "X" column, which is Bullish A move to $5.00 will be a double top and a break of that (very Bullish sign) brings us up the the long term trend line of $5.50~$6.00. After that we have open space until $7.50. Based upon the april 9th news and Dr. Reddy's recent investment, we are headed in the right direction and the chart is shaping up nicely. Plenty of cash on hand with upcoming catalyst can likely move us toward, and above the trend line. I remain Bullish and continue to like the risk/reward and have been adding at these levels.
0 · Reply
zampy
zampy Apr. 13 at 5:32 PM
$COYA This is changing very quickly we have a great Ceo at the helm...This is wirth 5x to 10x more!
1 · Reply
irf944
irf944 Apr. 13 at 5:03 PM
0 · Reply
Jwa68
Jwa68 Apr. 13 at 3:40 PM
$COYA $XBI https://alsnewstoday.com/news/scientists-identify-blood-markers-predict-als-progression/
0 · Reply
Jwa68
Jwa68 Apr. 13 at 3:07 PM
$COYA Coya retained the Japanese rights for ALS. Another value driving option... https://gmipost.com/coya-therapeutics-eyes-japan-as-it-advances-als-program/
0 · Reply
Jwa68
Jwa68 Apr. 12 at 4:35 PM
$COYA Coya has already shown data for 303 that it lowers inflammatory markers in a synergistic manner. Not much attention on this asset but this could untap value no one has their eyes on. Stay tuned...opportunity is fleeting https://www.instagram.com/reel/DW6xIEHjGa1/?igsh=NTBwd3N0MDNsaXl6
1 · Reply
zampy
zampy Apr. 12 at 1:35 PM
$COYA Dr Swaminathan became Chief Business officer at COYA. In less than 9 months this deal maker put together a 700m licensing deal with Dr Reddy's a 12 billion dollar company that trades under symbol RDY. Dr Swaminthan has a great reputation on Wall Street as a multi billion dollar deal maker. David Eihorn billionaire has participated in all funding rounds in 3 years plus. He believes this asset is worth considerably more. I believe Dr Swaminthan will provide an lucrative exit strategy for Eihorn and all concerned in the deal. I believe this is worth 5x to 10x. ALS is worth 3b to 5b per year, and FTD 4b to 6b. The stars are alligning here. The selling is a result of 1202 free stock after 5 years that is federally exempt. I believe the conflict has accelerated the selling the last 6 werks. Supply is running out. I believe we will see more institutions in the May 15th report 13F's. We have $2.50 in cash. The street is valuing us at $1.50 our science. STRONG BUY $25
1 · Reply
zampy
zampy Apr. 12 at 1:24 PM
$COYA Not sure many here realize what Ceo Dr Swaminathan has accomplished. He is a deal maker and I'll give an example of that as most have no idea. In 2019 to 2021 Dr Swaminathan was Chief Business officer at Alteogen KOSDAQ a prominent south korean biotech. He was the architect behind their international expansion and licensing strategies. During those years he put together massive deals totaling over 6 billion dollars. MERCK/ KEYTRUDA you see this advertised all day on t.v. Dr Swaminathan put this 6b deal together at Alteogen using their technolgyto develop subcutaneous version of Keytruda. Worth over 6b in milestones and royalties...While Dr Swaminthan was there KOSDAQ went from 400m to 4b market cap in just 2 years!!!! I doubt anyone knows this ir very frw we have a world class Ceo and deal maker knows what he is doing!!
0 · Reply
zampy
zampy Apr. 11 at 7:33 PM
$COYA A few weeks ago the FDA became less restrictive on people with hypertension meaning high blood pressure. People in the age bracket 50 to 59 ....55% are on blood pressure meds. Now in our study it is a direct signal from the FDA that it is a safety validation as well as mote people can enroll in our study with being on blood pressure medications! We will be even more expedious on the enrollment process!!! Dr Reddy's equity interest January along with Eihorn adding. Cash position 56m no debt. The FDA less restrictive 2 weeks ago. The biomarkers data suggest a much favorable trial outcome!!! THE STARS ARE ALLIGNING!!!RISK/REWARD is in our favor!!!
0 · Reply
Latest News on COYA
Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 2 months ago

Coya Therapeutics Announces $11.1 Million Private Placement


RealAvidTrader
RealAvidTrader Apr. 14 at 8:27 PM
$GANX $COYA Nice Health Consolidation Day - Gearing Up For Bigger Moves Later in The Year. Shareholders Should Be Very Excited, Optimistic For The Future. I Certainly Am!
0 · Reply
irf944
irf944 Apr. 14 at 2:18 PM
$COYA Pont & Figure chart update. I use P&F charts since they take the noise out of the daily volatility and trading prices. Coya had to omove from $3.75 to $4.50 to denote a change from Sellers/Supply (denoted by "O"), to Buyers/Demand (denoted by "X"). The stock is currently in the hands of buyers/demand, the "X" column, which is Bullish A move to $5.00 will be a double top and a break of that (very Bullish sign) brings us up the the long term trend line of $5.50~$6.00. After that we have open space until $7.50. Based upon the april 9th news and Dr. Reddy's recent investment, we are headed in the right direction and the chart is shaping up nicely. Plenty of cash on hand with upcoming catalyst can likely move us toward, and above the trend line. I remain Bullish and continue to like the risk/reward and have been adding at these levels.
0 · Reply
zampy
zampy Apr. 13 at 5:32 PM
$COYA This is changing very quickly we have a great Ceo at the helm...This is wirth 5x to 10x more!
1 · Reply
irf944
irf944 Apr. 13 at 5:03 PM
0 · Reply
Jwa68
Jwa68 Apr. 13 at 3:40 PM
$COYA $XBI https://alsnewstoday.com/news/scientists-identify-blood-markers-predict-als-progression/
0 · Reply
Jwa68
Jwa68 Apr. 13 at 3:07 PM
$COYA Coya retained the Japanese rights for ALS. Another value driving option... https://gmipost.com/coya-therapeutics-eyes-japan-as-it-advances-als-program/
0 · Reply
Jwa68
Jwa68 Apr. 12 at 4:35 PM
$COYA Coya has already shown data for 303 that it lowers inflammatory markers in a synergistic manner. Not much attention on this asset but this could untap value no one has their eyes on. Stay tuned...opportunity is fleeting https://www.instagram.com/reel/DW6xIEHjGa1/?igsh=NTBwd3N0MDNsaXl6
1 · Reply
zampy
zampy Apr. 12 at 1:35 PM
$COYA Dr Swaminathan became Chief Business officer at COYA. In less than 9 months this deal maker put together a 700m licensing deal with Dr Reddy's a 12 billion dollar company that trades under symbol RDY. Dr Swaminthan has a great reputation on Wall Street as a multi billion dollar deal maker. David Eihorn billionaire has participated in all funding rounds in 3 years plus. He believes this asset is worth considerably more. I believe Dr Swaminthan will provide an lucrative exit strategy for Eihorn and all concerned in the deal. I believe this is worth 5x to 10x. ALS is worth 3b to 5b per year, and FTD 4b to 6b. The stars are alligning here. The selling is a result of 1202 free stock after 5 years that is federally exempt. I believe the conflict has accelerated the selling the last 6 werks. Supply is running out. I believe we will see more institutions in the May 15th report 13F's. We have $2.50 in cash. The street is valuing us at $1.50 our science. STRONG BUY $25
1 · Reply
zampy
zampy Apr. 12 at 1:24 PM
$COYA Not sure many here realize what Ceo Dr Swaminathan has accomplished. He is a deal maker and I'll give an example of that as most have no idea. In 2019 to 2021 Dr Swaminathan was Chief Business officer at Alteogen KOSDAQ a prominent south korean biotech. He was the architect behind their international expansion and licensing strategies. During those years he put together massive deals totaling over 6 billion dollars. MERCK/ KEYTRUDA you see this advertised all day on t.v. Dr Swaminathan put this 6b deal together at Alteogen using their technolgyto develop subcutaneous version of Keytruda. Worth over 6b in milestones and royalties...While Dr Swaminthan was there KOSDAQ went from 400m to 4b market cap in just 2 years!!!! I doubt anyone knows this ir very frw we have a world class Ceo and deal maker knows what he is doing!!
0 · Reply
zampy
zampy Apr. 11 at 7:33 PM
$COYA A few weeks ago the FDA became less restrictive on people with hypertension meaning high blood pressure. People in the age bracket 50 to 59 ....55% are on blood pressure meds. Now in our study it is a direct signal from the FDA that it is a safety validation as well as mote people can enroll in our study with being on blood pressure medications! We will be even more expedious on the enrollment process!!! Dr Reddy's equity interest January along with Eihorn adding. Cash position 56m no debt. The FDA less restrictive 2 weeks ago. The biomarkers data suggest a much favorable trial outcome!!! THE STARS ARE ALLIGNING!!!RISK/REWARD is in our favor!!!
0 · Reply
zampy
zampy Apr. 11 at 6:20 PM
$COYA David Eihorn established a position in q4 2022...He is currently the largest shareholder and has participated in every round of funding as high as $7.50. Dr Reddy's RDY a 13 billion dollar company entered 2033 as their strategic partner. Now they are an equity investor. Pretty apparent That Dr Reddy's who put in an equity interest in January at $4.40 along with Eihorn believe in this science. At $4.17 investors can get it cheaper than RDY/EIHORN...$2.50 in cash...Currently EV is absurd 60m.... Overweighted position and will add next week....Biomarker data gives a successful probability of a favorable outcome.
0 · Reply
zampy
zampy Apr. 11 at 6:03 PM
$COYA So the data on the biomarkers from April 9th are dimply amazing. Thd baseline scores were 33.5. After 48 weeks it moved to 32 after 1 year QUITE REMARKABLE!!! So only lost 1.5 points vs people losing 1 point a month on placebo group!! UNPRECEDENTED!!!! My words. So before these results we had a 15% a successful result. now 45% or 166.7% better possibilty... These results will be UNPRECEDENTED!!! The 1202 stock coming out will regret it and I hope the enjoy their greasy chicken wings and schlitz beer!!! STRONG BUY ...$25 target
0 · Reply
RealAvidTrader
RealAvidTrader Apr. 11 at 5:52 PM
$COYA My Group Got a Buy Alert $3.70 Technical Level - I Believe $3.78 To Be Exact. Been Tracking This Company For Years Now, The First Time I Covered it, Stock Doubled And Ran to ATHs. Now Back Into Demand it is a No Brainer Here. Long Term Accumulation > Short Term Penny Flips. Excited is an Understatement
0 · Reply
foreverboner
foreverboner Apr. 11 at 12:57 AM
$COYA really wish the ppl who post a lot here would stop.
1 · Reply
zampy
zampy Apr. 10 at 7:33 PM
$COYA Please just sell all your beer $$$ for Friday your FREE stock and leave...Silver spoon a$$
0 · Reply
zampy
zampy Apr. 10 at 6:37 PM
$COYA In my strong opinion someone eith non priced stock is emptying out the till ..its being sold that way 1202 free stock....Federally exempt stock 5 urar paper.. This is my strong belief....Im 90% not always right but ...
0 · Reply
Jwa68
Jwa68 Apr. 10 at 3:25 PM
$COYA Considering buying this slight dip with some spare pocket change.
0 · Reply
zampy
zampy Apr. 10 at 3:24 PM
$COYA I believe buyers here $4.20 to $4.30 get rewarded....I believe this moron getting out has no cost basis and exempt from Federal taxes....Take advantage as yesterday we saw the data that gives us better odds of having a successful trial.
0 · Reply
zampy
zampy Apr. 10 at 3:07 PM
$COYA Irlando gets the trophy MORON OF THE DECADE
1 · Reply
zampy
zampy Apr. 10 at 3:03 PM
$COYA Its a moron that has free stock 1202....bot quite a few 4.20 to 4.27....morons abound..getting it cheaper than RDY/EIHORN....
0 · Reply
Orlandotrader
Orlandotrader Apr. 10 at 2:57 PM
$COYA Took 300,000 shares to put this at 4.50 and 38,000 to put this back essentially to the lows of yesterday. This investment was much too early as Readouts are not coming till 2027. Easy short target.
2 · Reply
Will2ride1
Will2ride1 Apr. 10 at 1:32 PM
$COYA nice candle...keep going
0 · Reply